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Abstract 26 
The aim of this work was the identification of new metabolites and transformation 27 
products (TPs) in chicken muscle from Enrofloxacin (ENR), Ciprofloxacin (CIP), 28 
Difloxacin (DIF) and Sarafloxacin (SAR), which are antibiotics that belong to the 29 
fluoroquinolones family. The stability of ENR, CIP, DIF and SAR standard solutions 30 
versus pH degradation process (from pH 1.5 to 8.0, simulating the pH since the drug is 31 
administered until its excretion) and freeze-thawing (F/T) cycles was tested. In addition, 32 
chicken muscle samples from medicated animals with ENR were analyzed in order to 33 
identify new metabolites and TPs. 34 
The identification of the different metabolites and TPs was accomplished by 35 
comparison of mass spectral data from samples and blanks, using liquid 36 
chromatography coupled to quadrupole time-of-flight (LC-QqToF) and Multiple Mass 37 
Defect Filter (MMDF) technique as a pre-filter to remove most of the background noise 38 
and endogenous components. Confirmation and structure elucidation was performed by 39 
liquid chromatography coupled to linear ion trap quadrupole Orbitrap (LC-LTQ-40 
Orbitrap), due to its mass accuracy and MS/MS capacity for elemental composition 41 
determination. 42 
As a result, 21 TPs from ENR, 6 TPs from CIP, 14 TPs from DIF and 12 TPs from SAR 43 
were identified due to the pH shock and F/T cycles. On the other hand, 14 metabolites 44 
were identified from the medicated chicken muscle samples. Formation of CIP and 45 
SAR, from ENR and DIF, respectively, and the formation of desethylene-quinolone 46 
were the most remarkable identified compounds. 47 
Keywords: Quinolones, chicken muscle, metabolites, transformation products, high-48 
resolution mass spectrometry. 49 
 50 
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1. Introduction 51 
Quinolones are one of the most widely used class of antibiotics in human and veterinary 52 
medicine. Their main uses in veterinary are therapeutic (treatment of bacterial 53 
infections), prophylactic (prevention of infections) and as growth promoters of animals 54 
intended for human consumption, although this last use is not allowed in the European 55 
Community [1,2].
 
 56 
Misuse of antibiotics in animals and the medicated animal slaughter before the 57 
metabolism and excretion of the antibiotic after therapeutic treatment, can lead to the 58 
presence and accumulation of residues of these antibiotics and their metabolites in food 59 
for human consumption. The intake of this food can result to health risks, such as 60 
allergy problems, toxicity and potential development of resistant bacterial strains when 61 
these antibiotic residues pass to humans through the food chain [3]. 62 
In order to regulate the use of these substances, to avoid risks to consumer health, the 63 
European Community has laid down a set of policies and measures, including the 64 
establishment of maximum residue limits (MRLs) for these antibiotics in animal food 65 
according to each species and tissue. A list of allowed substances, with MRL, is 66 
available in the Annex I of Commission Regulation 37/2010 [4,5]. However, this 67 
legislation generally include only the active compound (antibiotic) and in some cases, 68 
the main known metabolite. Other unknown metabolites and TPs possibly formed 69 
through the pH shock (from 1.2 in stomach to 8.0 in colon), interaction with biological 70 
substances or the own animal metabolism are not included in this Regulation. In 71 
addition, new TPs could be formed due to the complex sample treatment, which could 72 
be wrongly interpreted as metabolites and could contribute to pharmacological activity. 73 
Therefore, the identification of these unknown metabolites and TPs becomes necessary 74 
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to understand the possibly associated toxicity or harmful effects to human health and to 75 
avoid misleading results. 76 
In the literature, most of the TPs and metabolites described for quinolones come mainly 77 
from photo-degradation studies in environmental samples [6-12] and microbiological 78 
transformation products [13-20]. However, to our knowledge, studies focused on 79 
metabolites and TPs as antibiotic residues in animal tissues for human consumption, 80 
generated by biotransformation processes after pharmacological treatment, are scarcely 81 
described in the literature [21-23].   82 
Accordingly, the present study was focused on the effect of pH and F/T cycles on the 83 
formation of TPs from ENR, CIP, DIF and SAR, as well as the determination and 84 
identification of new metabolites and TPs from chicken muscle samples from medicated 85 
animals with ENR. 86 
 87 
 88 
 89 
 90 
 91 
 92 
 93 
 94 
 95 
 96 
 97 
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2. Experimental 98 
2.1. Reagents and materials 99 
Quinolones were purchased from different pharmaceutical firms: Enrofloxacin (ENR) 100 
from Cenavisa (Reus, Spain), Ciprofloxacin (CIP) from Ipsen Pharma (Paris, France), 101 
Difloxacin (DIF) and Sarafloxacin (SAR) from Abbot (Madrid, Spain). Quinolones 102 
were in their free form with a purity of ≥99%, according to the specifications of the 103 
pharmaceutical firms. 104 
Hydrochloric acid (HCl), acetic acid (HAcO), formic acid (HFo), trifluoroacetic acid 105 
(TFA), diethylmalonic acid (DEMA), ammonia (NH3), potassium dihydrogenphosphate 106 
(KH2PO4), sodium hydroxide (NaOH), methanol (MeOH, HPLC grade) and acetonitrile 107 
(MeCN, HPLC and MS grade) were provided from Merck (Darmstadt, Germany). 108 
Dichloroacetic acid (DCA) was provided from Carlo Erba (Milano, Italia) and 109 
ammonium acetate (NH4AcO, MS grade) from Sigma-Aldrich (St. Louis, MO, USA). 110 
Ultrapure water was obtained from a MilliQ system from Millipore (Billerica, MA, 111 
USA). Solid-phase extraction (SPE) cartridges Isolute ENV+ (3 mL / 200 mg) were 112 
supplied by Biotage AB (Uppsala, Sweden). The 22 and 45 µm nylon filter membranes 113 
by Sharlab (Barcelona, Spain) were used to filter the extracts before injection in the 114 
chromatographic system. 115 
 116 
2.2. Preparation of standard and working solutions 117 
Individual ENR, CIP, DIF and SAR stock solutions were prepared at a concentration of 118 
100 mg L
-1
 in HAcO 0.050 mol L
-1
.  119 
In order to investigate the generation of TPs at different pH values, buffers between pH 120 
1.5 and 8.0 were prepared to make the antibiotic working solutions. pH 1.5 was 121 
obtained from an aqueous solution of DCA 0.1% (v/v) and adjusted with HCl 1.0 mol L
-122 
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1
; pH 2.0 and 2.5 buffers were reached with HFo 0.1% (v/v) adjusted with HCl 1.0 mol 123 
L
-1
 and NH3 0.1 mol L
-1
, respectively; pH 3.0 and 3.5 buffers were obtained from HAcO 124 
0.1% (v/v) adjusted with HCl 0.1 mol L
-1
 and NH3 0.1 mol L
-1
, respectively; pH 4.5 and 125 
5.5 buffers were also obtained from HAcO 0.1% (v/v) adjusted with NH3 1.0 mol L
-1
. 126 
An aqueous solution of DEMA 0.010 mol L
-1
 was used for pH 6.5 and 8.0 buffers, the 127 
solution was adjusted with HCl 0.1 mol L
-1
 and NH3 1.0 mol L
-1
, respectively. 128 
Phosphate solution (0.050 mol L
-1
) was adjusted to pH 5.0 with NaOH 0.1 mol L
-1
. 129 
Hydroorganic solution TFA:H2O:MeCN (2:23:75, v/v/v) were also prepared. 130 
 131 
2.3. Instrumentation 132 
Liquid chromatography with ultraviolet detection (LC-UV) analyses were performed 133 
using an HP Agilent Technologies 1100 quaternary pump liquid chromatograph 134 
(Waldbronn, Germany).  135 
LC-MS analyses were performed using an Agilent 1200 RRLC binary pump liquid 136 
chromatograph (Waldbronn, Germany) coupled to a hybrid quadrupole time-of-flight 137 
QSTAR Elite Mass Spectrometer from Applied Biosystems (Concord, Ontario, 138 
Canada), equipped with a Turbo Ion Spray source.  139 
Both LC separations were carried out using an Agilent Zorbax Eclipse XDB-C8 column 140 
of 150 x 4.6 mm i.d. 5μm (Waldbronn, Germany) protected by a Kromasil C8 20 x 4.5 141 
mm i.d. 5μm guard column from Aplicaciones Analíticas (Barcelona, Spain), working 142 
at room temperature. 143 
LC-MS/MS analyses were performed using an Accela HPLC system from Thermo 144 
Fisher Scientific (Hemel Hempstead, UK) coupled to a linear ion trap quadrupole-145 
Orbitrap (LTQ-Orbitrap) Velos-Hybrid FT Mass Spectrometer from Thermo Fisher 146 
Scientific (Hemel Hempstead, UK), equipped with a heated electrospray ionization 147 
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(HESI) interface. The LC separation was carried out using a Waters Simmetry C8 50 x 148 
2.1 mm i.d. 5μm (Milford, Massachusetts, USA), working at room temperature. 149 
SPE was carried out on a SUPELCO vacuum manifold connected to a SUPELCO 150 
vacuum tank (Bellefone, PA, USA). 151 
Auxiliary apparatuses were: a CRISON 2002 potentiometer (±0.1 mV) (Barcelona, 152 
Spain) equipped with a CRISON 5203 combined pH electrode from Orion Research 153 
(Boston, MA, USA) used to measure the pH of the buffer solutions; a centrifuge 460R 154 
of Hettich Zentrifugen (Tuttlingen, Germany) used in sample treatment and a TurboVap 155 
LV system from Caliper LifeSciences (Hopkinton, MA, USA) with nitrogen stream for 156 
the evaporation of the extracts. An analytical balance with a precision of ±0.1 mg and a 157 
vortex-mixer were also used. 158 
 159 
2.4. Procedures 160 
2.4.1. Preliminary stability studies 161 
In order to study the stability of quinolones versus pH and F/T cycles, stock solutions of 162 
each antibiotic were diluted in each buffer solution (pH values from 1.5 to 8.0) to obtain 163 
a concentration of 10 mg L
-1
 and analyzed after 1, 2 and 3 F/T cycles at -20ºC. Samples 164 
were kept at -20ºC for 24h between each F/T cycle. 165 
In addition, blanks were prepared taking 100 µL from the 0.050 mol L
-1
 HAcO solution 166 
and were diluted in each buffer solution. 167 
 168 
2.4.2. Medicated animal samples 169 
Chicken muscle samples from medicated animals with ENR were analyzed. Chickens 170 
were medicated according to the pharmacological administration protocol fit for human 171 
consumption. The therapeutic treatment involved a daily dose of 16 mg/kg of ENR 172 
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dissolved in the chicken drinking water during 4 days. Fresh pre-solutions of the 173 
antibiotic and the medicated water were prepared every day just before it is offered to 174 
the animals. Two types of samples were analyzed; two male broiler chickens 175 
slaughtered on the third day of the pharmacological treatment (3-day treated) and two 176 
male broiler chickens slaughtered four days after pharmacological treatment ends (post-177 
treatment). In addition, two male broiler chickens (non-medicated chickens) randomly 178 
selected from the poultry farm were sacrificed and used as blanks. Chickens were 179 
sacrificed after 23 days (3-day treated) and 28 days (post-treatment and blanks) of life. 180 
Meat was minced, homogenized and stored at -20ºC until sample treatment. 181 
 182 
2.4.3. Sample preparation 183 
Samples were processed according to a validated LC-MS/MS multi-residue method for 184 
the determination of β-lactams compounds in animal tissue [24,25], modifying the 185 
elution stage of the SPE. In order to determine if the method for β-lactams was also 186 
valid for quinolones, recoveries from spiked muscle samples with the four studied 187 
quinolones were carried out. Results showed a recovery of 81.6% for ENR, 62.6% for 188 
CIP, 73.2% for DIF and 70.5% for SAR, which were considered acceptable values. 189 
Briefly, antibiotics were extracted from 4g (± 0.1mg) of minced chicken muscle with a 190 
mixture of 2mL of MilliQ water and 20mL of MeCN. After shaking for 2 min, the 191 
mixture was centrifuged at 3500 rpm (5 min) and the obtained hydroorganic extract was 192 
evaporated under N2 stream in a TurboVap system at 35ºC until 2mL as final volume. 193 
25mL of 0.050 mol L
-1
 phosphate solution at pH 5.0 was added to the remaining 194 
aqueous extract and the resulting mixture was processed by SPE. The Isolute ENV+ 195 
cartridges were activated with 2mL of MeOH, 2mL of MilliQ water and 2mL of 0.050 196 
mol L
-1
 phosphate solution at pH 5.0. The muscle extract was then loaded to the 197 
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cartridge and washed with 3mL of phosphate solution at pH 5.0 and 1mL of MilliQ 198 
water, followed by the elution of the analytes with 5mL of the hydroorganic solution 199 
TFA:H2O:MeCN (2:23:75, v/v/v) and 1mL of MeCN. The produced SPE eluates were 200 
evaporated to dryness at 35ºC under N2 stream and reconstituted with 200µL of MilliQ 201 
water. Prior to injection, samples were filtered and stored at -20ºC. 202 
An aliquot of 20µL and 10µL of the extracts were injected into the chromatographic 
203 
system for the LC-QqToF and LC-LTQ-Orbitrap experiments, respectively. 
204 
 205 
2.4.4. Instrumental conditions 206 
LC-UV and LC-QqToF analyses were performed at a constant flow rate of 1.0 mL min
-1
. 207 
LC-LTQ-Orbitrap analyses were performed at a constant flow rate of 0.3 mL min
-1
. In 208 
all cases, the same binary solvent system was used: solvent A, 0.005 mol L
-1
 NH4AcO 209 
adjusted at pH 2.5 with HFo and solvent B, MeCN.  210 
LC-UV analyses gradient system was programmed as follows: initially 12% B, from 0 211 
to 7.5 min B was maintained at 12%, from 7.5 to 23.5 min B was linearly increased to 212 
29% and from 23.5 to 25 min decreased to 28%. Finally B decreased to initial 213 
conditions in 1 min and maintained at this percentage for 2 min. The detection was 214 
carried out at 280 nm for all quinolones. Acquisition and data processing were 215 
performed by ChemStation software Agilent Technologies (Waldbronn, Germany). 216 
LC-QqToF analyses gradient system was programmed as follows: initially 14% B, from 217 
0 to 5 min B increased to 21%, from 5 to 6 min B increased to 24%, from 6 to 7.5 min B 218 
increased to 25%, from 7.5 to 9 min B increased to 54% and then maintained at 54% for 219 
0.5 min. Finally B decreased to 14% in 0.5 min and maintained at this percentage for 3 220 
min. A T-piece splitter (3:1) was used to reduce the ﬂow-rate entering into the 221 
electrospray ionization source. Working in positive ionization mode, optimized 222 
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instrument parameters settings were the following: Ion Spray (IS) voltage was 4500V; 223 
gas temperature 400 ºC; Declustering Potencial (DP) 60 V; Focusing Potencial (FP) 350 224 
V and Declustering Potential 2 (DP2) 10 V. Mass spectrometry analyses were carried 225 
out on full-scan MS mode, working at a resolving power of 10000 and with a mass 226 
range of 100–1000 Da at a scan rate of 1s per spectrum. Analyst QS version 2.0 and 227 
Peak View 1.2 from Applied Biosystems (Toronto, Canada) were used for the 228 
acquisition and data processing, respectively. 229 
LC-LTQ-Orbitrap analyses gradient system was programmed as follows: initial 3% B, 230 
from 0 to 5 min B increased to 25%, from 5 to 6 min B increased to 35%, from 6 to 7 231 
min B increased to 55% and then maintained at this percentage for 1 min. Finally B 232 
decreased to 3% in 1.5 min and maintained at this percentage for 3 min. Mass 233 
spectrometry analyses were carried out on full-scan MS and product ion scan MS/MS 234 
modes with a mass range of 100–1000 Da. The resolving power was 30000 and 15000 235 
for the full-scan and MS/MS events, respectively. Employing positive ionization mode, 236 
a multiple component detection method was used as a default values of the parameters 237 
settings to carry out the different experiments. A source voltage of 3500V and a 238 
capillary temperature of 300ºC were used as main parameters settings. Collision energy 239 
(HCD) of 40-70% was used for the MS/MS experiments. Acquisition and data 240 
processing were performed by Xcalibur 2.1 QualBrowser from Thermo Fisher Scientific 241 
(Hemel Hempstead, UK). 242 
 243 
2.4.5. Data processing 244 
Metabolites and TPs identification in the medicated chicken muscle samples were 245 
performed by processing the accurate-mass full-scan raw data by MMDF [26-28] using 246 
Peak View 1.2 from Applied Biosystems (Toronto, Canada). ENR (m/z 360.1718), CIP 247 
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(m/z 332.1405), the core substructure with m/z 263.0826, formed by the piperazine ring 248 
loss, and the glucuronide conjugation of ENR (m/z 536.2039), were used as MDF 249 
templates. The MDF window was set to ±40 mDa around the mass defects of the 250 
templates over a mass range of ±50 Da around the filter template masses. The use of 251 
MMDF technique as a pre-filter enabled the reduction of most of the false-positive 252 
peaks (endogenous components) and background interferences. 253 
Once the data was filtered, comparison of mass spectral data between samples and 254 
blanks enabled to differentiate the metabolite ions of interest from interference ions in 255 
the biological matrix, especially those ions that show a very low intensity by LC-MS. 256 
The identification of the different TPs in the preliminary stability study was performed 257 
directly by comparison of mass spectral data from samples and blanks. 258 
The confirmation and structure elucidation of the identified metabolites and TPs were 259 
carried out by the MS/MS spectrum generated by the product ion scan of each ion.  260 
 261 
3. Results and discussion 262 
3.1. Effect of pH and F/T cycles 263 
Figure 1 shows the effect of pH on ENR, CIP, DIF and SAR after applying three F/T 264 
cycles for each pH value. Areas were obtained by LC-UV and rescaled to values 265 
between 0 and 1 (relative values) for each pH value and F/T cycle, which enabled a 266 
better visualization and interpretation of the variation of the compound depending on 267 
the pH or the number of applied F/T cycles. Rescaling was accomplished by dividing 268 
the area obtained for each pH value and F/T cycle by the larger area of those areas 269 
obtained for the compound. This procedure was carried out for each compound. 270 
Considering that a degradation lower than 10% negligible, at extreme pH values, the 271 
compounds do not show significant degradation after applying three F/T cycles. 272 
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However, at pH values between 2.5-3.5 and 6.5, a degradation around 15-25% is 273 
observed for the four studied quinolones. At these pH values, significant degradation is 274 
observed after applying the first F/T cycle, whereas for the rest of the pH values, 275 
degradation is less pronounced when increasing the number of applied F/T cycles. 276 
 277 
3.1.1. Transformations products 278 
Table 1 shows a summary of the observed TPs from ENR, CIP, DIF and SAR standard 279 
solutions when were subjected to different conditions of pH and after applying three F/T 280 
cycles. In Table 1, mass spectral data and MS/MS spectrum for each compound are shown. 281 
Proposed structures for each compound are shown in Figures 2 and 3.  282 
According to the structure for each compound, main degradation processes of ENR, CIP, 283 
DIF and SAR are piperazine ring and aromatic core transformations. Main degradation 284 
steps involved in the piperazine ring substituent were ring cleavage and once the ring has 285 
been cleaved, the resulted primary or secondary amine undergoes further degradation that 286 
leads to methylated, formylated and acetylated products in positions 1 and 4 of the 287 
piperazine ring. Other degradation conversions are oxidative steps (oxo-formation), 288 
hydroxylation and methylation in positions 2 and 3 of the piperazine ring, as well as N-289 
oxidation, N-hydroxylation, N-formylation, N-acetylation, N-demethylation and N-290 
deethylation, with or without subsequent ring cleavage, in position 4 of the piperazine ring. 291 
Aromatic core reactions were mainly based on the hydroxylation at the two available 292 
positions on the aromatic ring, as well as the defluorination of the molecule. 293 
Decarboxylated compound were also observed for ENR and SAR, as well as combinations 294 
of piperazine ring and aromatic core based reactions. 295 
TPENR-1, TPENR-3, TPENR-5, TPENR-9, TPENR-10, TPENR-13, TPENR-14, 296 
TPENR-17, TPENR-18, TPCIP-1, TPCIP-4, TPDIF1, TPDIF-3, TPDIF-7, TPSAR-3 and 297 
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TPSAR-6 are quinolone structures described in literature as photo-degradation products in 298 
environmental samples [6-12] and microbiological transformation products [13-20] but, to 299 
our knowledge, the rest of the observed compounds have not been described previously. 300 
From the intensity showed by LC-MS, the different compounds can be divided in three 301 
groups. In the first group TPENR-20, TPCIP-5, TPDIF-13, TPSAR-11 and TPENR-21, 302 
TPCIP-6, TPDIF-14, TPSAR-12 are included. Those ones are structure related compounds 303 
and show the most intense signal. These compounds could be formed by quinolone 304 
degradation and interaction with reagents present in the medium. The second group would 305 
be formed by TPENR-3 (CIP) and TPDIF-3 (SAR), formed via N-desethylation and N-306 
desmethylacion of ENR and DIF, respectively, and TPENR-5, TPCIP-1, TPDIF-1 and 307 
TPSAR-3, formed by piperazine ring cleavage (deethylation). In the third group would be 308 
the rest of the compounds, which show a very low intensity.  309 
Figure 4 shows the effect of pH on the main observed TPs for each quinolone. Peak 310 
areas were rescaled following the same procedure indicated in section 3.1. As Figure 4 311 
shows, all TPs were formed at all pH values and most of them show the same behavior 312 
than ENR, CIP, DIF and SAR. At pH values between 2.5-3.5 and 6.5 were less formed 313 
than for the rest of pH values, except for TPENR-20, TPCIP-5, TPDIF-13, TPSAR-11 and 314 
TPENR-21, TPCIP-6, TPDIF-14, TPSAR-12, which show just the opposite behavior. 315 
Therefore, the formation of those TPs could explain the behavior showed by the four 316 
studied quinolones and the rest of TPs. 317 
 318 
3.2. Medicated animal samples 319 
Chicken muscle samples from medicated animals with ENR (explained in section 2.4.2) 320 
were analyzed with the purpose of identifying those unknown metabolites and TPs 321 
which could be present in the animal tissue and therefore, can lead to health risks when 322 
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pass to humans through the food chain. These metabolites and TPs could be formed by 323 
interaction with biological substances, biotransformation reactions that occur in the own 324 
animal (metabolism) or even originated by the complex sample treatment.  325 
Table 2 shows a summary of the identified metabolites obtained from the chicken 326 
muscle samples from the medicated animals with ENR. In Table 2, mass spectral data, 327 
MS/MS spectrum and the proposed structure for each metabolite are shown. 328 
According to the proposed structure for each metabolite shown in Table 2, main 329 
biotransformation processes of ENR due to the animal metabolism are piperazine ring 330 
transformations as occur in preliminary study. Piperazine ring cleavage (M1 and M3), 331 
piperazine ring cleavage and the subsequent addition of methyl and acetyl groups in 332 
positions 1 and 4 (M6 and M11), oxidation in position 2 (M8 and M14) and N-333 
deethylation, N-demethylation, N-acetylation and N-hydroxylation in position 4 of the 334 
piperazine ring (M2, M5, M9 and M12) were observed. Aromatic core biotransformation 335 
reactions were also observed, mainly based on the hydroxylation of the aromatic ring and 336 
the defluorination of the molecule, with or without subsequent hydroxylation, such as M4, 337 
M10 and M13. Other biotransformation processes combined piperazine ring and aromatic 338 
core based reactions, such as M7 and M10. 339 
The two most abundant observed metabolites were M2, formed by the N-desethylation 340 
of ENR, leading to ciprofloxacin [14,15,18,20,21], and M3, originated by the piperazine 341 
ring cleavage (deethylation), leading to desethylene-enrofloxacin [14,15,18,20,21]. 342 
Other metabolites which had a great abundance in the samples were M1, M4 and M10.  343 
As for the grade of the animal metabolism, after four days of pharmacological treatment 344 
ends, the animal metabolized and excreted most of the metabolites. However, the 345 
supplied antibiotic (ENR) and some of the metabolites observed after three days of 346 
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pharmacological treatment (M1, M2, M3, M4 and M10) still remain in the animal 347 
muscle tissue. 348 
As occur for ciprofloxacin (M2) and desethylene-enrofloxacin (M3), M1, M8, M9, M10 349 
and M14 are quinolone structures described in literature as microbiological 350 
biotransformation products [14,15,18,20] and metabolite residues of ENR in animal 351 
tissues for human consumption [21], but M4, M5, M6, M7, M11, M12 and M13 have 352 
not been described previously in the literature 353 
Metabolites M1, M2, M3, M6, M8, M9, M11, M12, M13 and M14 were also observed 354 
as TPs in the preliminary study (TPENR-1, TPENR-3, TPENR-5, TPENR-8, TPENR-9, 355 
TPENR-10, TPENR-13, TPENR-15, TPENR-16 and TPENR-17, respectively). 356 
 357 
3.2.1. Structural elucidation of the main metabolites 358 
In general, the loss of water [M+H-H2O]
+, the loss of the carboxyl moiety [M+H−CO2]
+
 359 
and the loss of the fluoride [M+H-HF]
+
 are characteristic fragmentation pathways for 360 
fluoroquinolones [11,29]. Moreover, ENR in particular shows the loss of the 361 
cyclopropyl group [M+H−C3H5˙]
+ 
and the N-desethylation followed by the degradation 362 
steps of the piperazinyl moiety [M+H−C2H4-C2H5N]
+
 (see ENR in Table 2). Thus, the 363 
appearance of these fragmentations in the MS/MS spectrum can give hints, for example, 364 
at the existence of an intact carboxyl moiety or an intact piperazinyl moiety. Figure 5 365 
shows the MS/MS spectra of the main metabolites. 366 
The compound with m/z 263.0822 (Figure 5A) displayed all typical product ions of 367 
ENR, giving the loss of H2O (m/z 245.0722), the loss of the cyclopropyl group (m/z 368 
222.0436), decarboxylation and desaturation (m/z 217.0772), the combined loss of H2O 369 
and the cyclopropyl group (m/z 204.0330) and the combined loss of the carboxyl group, 370 
a carbonyl group and the partial cyclopropyl group cleavage (m/z 177.0824), except for 371 
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the degradation of the piperazinyl moiety. Consequently, it reflects an ENR derivative 372 
with a NH3 substituent in position 7 as is the case for M1 (Table 2). 373 
MS/MS measurements of the compound with m/z 332.1405 (Figure 5B) showed typical 374 
fragmentation pathways such as the loss of H2O leading to m/z 314.1302, the loss of the 375 
carboxyl group resulting in m/z 288.1509 and the combined loss of the carboxyl group 376 
and fluoride yielding m/z 268.1445. These fragments do not hint any plausible structure, 377 
but the combined fragments of m/z 245.1087, originated by the loss of the carboxyl 378 
group and the piperazinyl moiety, m/z 231.0928 equivalent to the loss of the carboxyl 379 
group and the further degradation of the piperazine ring and m/z 204.0693, which 380 
combines the loss of the carboxyl group, the piperazinyl moiety and the loss of the 381 
cyclopropyl group, reflects the absence of a N-ethyl group in position 4 of the molecule, 382 
which indicates that the compound with m/z 332.1405 can be assigned to the proposed 383 
structure for M2 (Table 2). 384 
The compound with m/z 334.1556 showed also typical fragmentation pathways (Figure 385 
5C) such as the loss of fluoride leading to m/z 314.1500, the combined loss of H2O and 386 
fluoride yielding m/z 296.1395, the combined loss of the carboxyl group, desaturation 387 
and fluoride resulting in m/z 268.1445 and the combined loss of H2O, fluoride and the 388 
cyclopropyl group giving the fragment with m/z 255.1003. The fragments with m/z 389 
289.0983, originated by the loss of an ethyl group and NH3 and m/z 245.1087 due to the 390 
combined loss of the carboxyl group, an ethyl group and NH3, and moreover, the 391 
fragments with m/z 263.0827 and m/z 219.0928 in whose structures remains only a 392 
primary amine as substituent in position 7, in combination with the lack of the typical 393 
piperazinyl moiety fragment ions, suggests the piperazine ring cleavage, which is in 394 
agreement with the proposed structure for M3 (Table 2). 395 
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The substance with m/z 342.1806 (Figure 5D) possessed the fragment ions of the loss of 396 
H2O, which leads to m/z 324.1707, the loss of the carboxyl group giving m/z 298.1912 397 
and the combined loss of H2O, followed by N-desethylation and desethylation due to 398 
the piperazine ring cleavage resulting in m/z 268.1081, as well as the combined loss of 399 
the carboxyl group, N-desethylation and degradation of the piperazinyl moiety yielding 400 
m/z 227.1178, and the decarboxylation, N-desethylation and further degradation of the 401 
piperazinyl moiety leading to m/z 213.1021. However, the lack of the typical fluoride 402 
loss fragment ion suggests the absence of the fluoride according to the proposed 403 
structure for M4 (Table 2). 404 
MS/MS measurements of the compound with m/z 374.1701 (Figure 5E) show the loss 405 
of H2O (m/z 356.1602), the loss of the carboxyl group (m/z 330.1970), the combined 406 
degradation of the piperazinyl moiety and N-desethylation (m/z 303.0971) and the 407 
combined N-desethylation, loss of H2O and the degradation of the piperazinyl moiety 408 
(m/z 285.0868). Furthermore, N-desethylation and a further degradation of the 409 
piperazine ring give the fragment with m/z 277.0817 and the combined loss of the 410 
carboxyl group, desaturation, N-desethylation and the piperazinyl moiety leads to m/z 411 
257.0919. Subtraction between molecular formulas of ENR and the identified m/z 412 
374.1701, obtained by the QualBrowser software from Thermo Fisher Scientific, gives 413 
a difference of [M+2H+2O-F]
+
, which suggests the defluorination of the molecule and 414 
the addition of two hydroxyl groups. The lack of the typical fluoride loss fragment ion 415 
and the absence of the loss of a hydroxyl group from the combined piperazine ring 416 
fragments ions in the MS/MS spectrum, suggest that the metabolite was originated by 417 
the replacement of the fluoride for a hydroxyl group and the hydroxylation of the 418 
aromatic core in one of the two available positions, as reflects the proposed structure for 419 
M10 shown in Table 2.  420 
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4. Conclusions 421 
A total of 21 TPs from ENR, 6 TPs from CIP, 14 TPs from DIF and 12 TPs from SAR 422 
were identified due to the pH shock and F/T cycles, where the formation of CIP and 423 
SAR, from ENR and DIF, respectively, the formation of desethylene-quinolone and the 424 
formation of TPENR-20, TPCIP-5, TPDIF-13, TPSAR-11 and TPENR-21, TPCIP-6, 425 
TPDIF-14, TPSAR-12, were the most remarkable observed compounds. The four 426 
quinolones showed a sharp instability at pH values between 2.5-3.5 and 6.5, which 427 
could be explained by the formation of two related structure compounds for each one 428 
(TPENR-20, TPCIP-5, TPDIF-13, TPSAR-11 and TPENR-21, TPCIP-6, TPDIF-14, 429 
TPSAR-12).  430 
In the analysis of the chicken muscle samples from the medicated animals with ENR, a 431 
total of 14 metabolites were identified. Formation of CIP (M2) and desethylene-432 
enrofloxacin (M3) were the most abundant observed metabolites. The animal 433 
metabolized and excreted most of the metabolites after four days the medical treatment 434 
ended, but residues of ENR and some metabolites (M1, M2, M3, M4 and M10) still 435 
remained in the animal muscle tissue. 436 
Regarding to the main degradation and biotransformation processes of quinolones 437 
observed in both studies, stand out piperazine ring and aromatic core based reactions. 438 
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Figure captions 539 
Figure 1. Effect of pH and F/T cycles on standard solutions of ENR, CIP, DIF and SAR. 540 
Symbols: 541 
 542 
 543 
Figure 2. Proposed structures for the identified TPs from ENR (A) and CIP (B) standard 544 
solutions at different pH values. 545 
 546 
Figure 3. Proposed structures for the identified TPs from DIF (A) and SAR (B) standard 547 
solutions at different pH values. 548 
 549 
Figure 4. Effect of pH on major TPs. 550 
 551 
Figure 5. MS/MS spectra of the main identified metabolites of ENR in the medicated 552 
chicken samples. A) M1, B) M2, C) M3, D) M4 and E) M10. 553 
 
     0 cycles      1st cycle      2nd cycle      3rd cycle 
Table 1. Mass spectral data and MS/MS spectrum of the identified TPs from ENR, CIP, DIF and SAR due to pH shock and F/T cycles. 
Compound [M+H]+exp 
RT 
(min) 
Molecular Formula [M+H]+theo 
m/z error 
(ppm) 
MS/MS spectrum 
ENR 360.1715 4.90 [C19H23N3O3F]
+ 360.17180 -0.8 360.1719, 342.1612, 340.1656, 316.1820, 286.0986, 257.1085, 245.1085, 231.0928 
TPENR-1* 263.0820 6.79 [C13H12N2O3F]
+ 263.08265 -2.5 263.0829, 245.0722,  222.0436, 217.0772, 204.0330, 177.0824 
TPENR-2 316.1813 4.20 [C18H23N3OF]
+ 316.18197 -2.1 316.1829, 296.1767, 268.1451, 260.1202, 245.1092, 231.0934, 204.0698 
TPENR-3* 332.1407 4.60 [C17H19N3O3F]
+ 332.14050 0.6 332.1407, 314.1302, 288.1509, 268.1445, 245.1087, 231.0928, 204.0693 
TPENR-4 334.1187 6.47 [C16H17N3O4F]
+ 334.11976 -3.2 334.1195, 316.1090, 299.0842, 289.0970, 271.0874, 263.0826, 245.0720, 217.0406 
TPENR-5* 334.1553 4.44 [C17H21N3O3F]
+ 334.15615 -2.5 334.1561, 314.1500, 296.1395, 289.0983, 268.1445, 263.0827, 255.1003, 245.1087, 219.0928 
TPENR-6 348.1346 6.10 [C17H19N3O4F]
+ 348.13541 -2.3 348.1352, 330.1248, 302.1298, 289.0976, 287.1428, 285.1267, 245.1084 
TPENR-7 348.1353 6.64 [C17H19N3O4F]
+ 348.13541 -0.3 348.1352, 330.1246, 313.1003, 288.1152, 271.0876, 263.0822, 230.0483, 217.0406 
TPENR-8* 348.1710 4.78 [C18H23N3O3F]
+ 348.17180 -2.3 348.1718, 304.1818, 273.1269, 245.1084, 233.1084, 219.0927, 205.0771 
TPENR-9* 374.1498 3.99 [C19H21N3O4F]
+ 374.15106 -3.4 374.1510, 356.1411, 346.1557, 314.0937, 289.0981, 286.0985, 275.0827, 271.0877, 257.0724 
TPENR-10* 374.1502 7.49 [C19H21N3O4F]
+ 374.15106 -2.3 374.1511, 356.1406, 332.1029, 314.1301, 295.0951, 272.0829, 243.0562, 231.0564 
TPENR-11 374.1865 5.24 [C20H25N3O3F]
+ 374.18745 -2.5 374.1871, 356.1765, 330.1974, 302.1659, 286.0980, 271.1239, 259.1241, 245.1086, 205.0770 
TPENR-12 376.1294 7.61 [C18H19N3O5F]
+ 376.13033 -2.5 376.1306, 348.1353, 334.1187, 330.1247, 316.1086, 289.0982, 262.0748 
TPENR-13* 376.1660 4.60 [C19H23N3O4F]
+ 376.16671 -1.9 376.1668, 358.1561, 346.1548, 289.0983, 275.0824, 262.0749, 244.1012 
TPENR-14 376.1657 5.00 [C19H23N3O4F]
+ 376.16671 -2.7 376.1668, 358.1558, 332.1765, 305.0930, 301.1216, 261.1034, 233.0720 
TPENR-15* 376.1662 5.27 [C19H23N3O4F]
+ 376.16671 -1.4 376.1669, 359.1639, 344.1404, 330.1614, 315.1740, 300.1507, 287.1429 
TPENR-16* 376.1655 5.77 [C19H23N3O4F]
+ 376.16671 -3.2 376.1666, 332.1767, 301.1219, 261.1036, 247.0879, 220.0642 
TPENR-17* 388.1297 6.64 [C19H19N3O5F]
+ 388.13033 -1.6 388.1305, 360.1367, 348.0995, 342.1262, 330.0885, 320.1048, 302.0571 
TPENR-18 390.1449 6.75 [C19H21N3O5F]
+ 390.14598 -2.8 390.1472, 372.1361, 362.1514, 320.1053, 305.0936, 291.0783, 273.0674, 259.0519, 231.0568 
TPENR-19 390.1449 7.08 [C19H21N3O5F]
+ 390.14598 -2.8 390.1468, 372.1359, 362.1518, 320.1045, 299.0839, 291.0781, 273.0674, 259.0519, 231.0568 
TPENR-20 462.1595 0.50 [C20H24N5O8]
+ 462.16194 -5.3 462.1621, 444.1511, 436.1827, 418.1723 
TPENR-21 490.1560 0.50 [C21H24N5O9]
+ 490.15685 -1.7 490.1562, 476.1408, 448.1459, 422.1668, 404.1563, 394.1721, 378.1770, 376.1612, 360.1663 
CIP 332.1405 4.70 [C17H19N3O3F]
+ 332.14050 0.0 332.1407, 314.1302, 312.1345, 288.1509, 268.1445, 245.1087, 231.0928, 204.0693 
TPCIP-1 306.1241 4.31 [C15H17N3O3F]
+ 306.12485 -2.4 306.1255, 288.1148, 286.1190, 268.1084, 263.0830, 245.0722, 236.0595, 227.0692, 217.0410 
TPCIP-2 346.1188 5.96 [C17H17N3O4F]
+ 346.11976 -2.8 346.1196, 328.1087, 284.1186, 275.0824, 257.0721, 242.0721, 229.0771 
TPCIP-3 346.1548 4.75 [C18H21N3O3F]
+ 346.15615 -3.9 346.1559, 328.1457, 302.1663, 285.1269, 257.1085, 245.1084, 231.0928, 204.0691 
TPCIP-4 360.1344 7.35 [C18H19N3O4F]
+ 360.13541 -2.8 360.1351, 342.1221, 318.0888, 301.0848, 286.0984, 272.0826, 261.0663, 248.0589, 243.0562 
TPCIP-5 434.1297 0.46 [C18H20N5O8]
+ 434.13064 -2.2 434.1310, 416.1203, 408.1516, 390.1413 
TPCIP-6 462.1257 0.46 [C19H20N5O9]
+ 462.12555 0.3 462.1259, 448.1092, 420.1149, 394.1356, 376.1251, 366.1404, 350.1456, 348.1300, 332.1349 
DIF 400.1466 5.43 [C21H20N3O3F2]
+ 400.14672 -0.3 400.1469, 382.1362, 356.1572, 336.1508, 311.0991, 299.0993, 285.0835 
TPDIF-1 374.1310 5.21 [C19H18N3O3F2]
+ 374.13107 -0.2 374.1317, 354.1253, 343.0894, 336.1148, 325.0787, 317.0738, 308.1198, 299.0994, 280.1248 
TPDIF-2 382.1557 5.20 [C21H21N3O3F]
+ 382.15615 -1.2 382.1566, 364.1460, 338.1665, 321.1276, 308.1559, 293.1086, 281.1088, 267.0930 
TPDIF-3 386.1308 5.34 [C20H18N3O3F2]
+ 386.13107 -0.7 386.1316, 366.1254, 342.1416, 322.1352, 299.0993, 285.0836, 279.0930 
TPDIF-4 414.1250 4.69 [C21H18N3O4F2]
+ 414.12599 -2.4 414.1262, 386.1316, 368.1200, 347.1063, 343.0894, 329.0734, 325.0784, 311.0627 
TPDIF-5 414.1616 5.68 [C22H22N3O3F2]
+ 414.16237 -1.9 414.1622, 370.1726, 339.1176, 313.1146, 299.0989, 285.0835 
TPDIF-6 416.1401 4.78 [C21H20N3O4F2]
+ 416.14164 -3.7 416.1417, 398.1300, 371.0840, 343.0895, 327.0938, 299.0990 
TPDIF-7 416.1413 5.05 [C21H20N3O4F2]
+ 416.14164 -0.8 416.1422, 398.1316, 386.1314, 353.1170, 343.0891, 329.0732, 316.0657 
TPDIF-8 416.1403 5.45 [C21H20N3O4F2]
+ 416.14164 -3.2 416.1417, 398.1311, 372.1522, 350.0941, 315.0936, 301.0785 
TPDIF-9 416.1410 5.82 [C21H20N3O4F2]
+ 416.14164 -1.5 416.1416, 372.1521, 359.0841, 341.0733, 315.0943, 287.0628, 274.0675 
TPDIF-10 430.1203 5.72 [C21H18N3O5F2]
+ 430.12090 -1.4 430.1218, 402.1264, 373.0671, 356.0848, 343.0892, 329.0734, 317.0734, 299.0994 
TPDIF-11 430.1208 7.15 [C21H18N3O5F2]
+ 430.12090 -0.2 430.1210, 412.1107, 402.1258, 384.1161, 356.0843, 345.0679, 327.0577, 317.0730, 299.0629 
TPDIF-12 430.1210 7.36 [C21H18N3O5F2]
+ 430.12090 0.2 430.1209, 412.1100, 402.1260, 384.1164, 356.0844, 345.0680, 327.0572, 317.0732 
TPDIF-13 502.1363 0.52 [C22H21N5O8F]
+ 502.13687 -1.1 502.1365, 484.1268, 476.1569, 458.1472 
TPDIF-14 530.1308 0.52 [C23H21N5O9F]
+ 530.13178 -1.8 530.1312, 516.1155, 488.1219, 462.1418, 444.1317, 434.1475, 418.1526, 416.1359, 400.1422 
SAR 386.1311 5.38 [C20H18N3O3F2]
+ 386.13107 0.1 386.1315, 368.1206, 366.1249, 342.1415, 340.1260, 322.1351, 299.0992, 285.0836 
TPSAR-1 318.0566 7.92 [C16H10NO4F2]
+ 318.05724 -2.0 318.0574, 300.0467, 272.0518, 256.0568, 244.0569, 224.0505 
TPSAR-2 342.1412 4.91 [C19H18N3OF2]
+ 342.14125 -0.1 342.1417, 322.1353, 299.0994, 294.1042, 285.0837 
TPSAR-3 360.1154 5.15 [C18H16N3O3F2]
+ 360.11542 -0.1 360.1159, 343.0893, 340.1096, 322.0990, 317.0737, 299.0993, 294.1041, 279.0931, 266.1091 
TPSAR-4 398.1498 5.31 [C21H21N3O4F]
+ 398.15106 -3.2 398.1516, 380.1409, 354.1615, 337.1221, 311.1193, 297.1037, 281.0724 
TPSAR-5 402.1247 5.11 [C20H18N3O4F2]
+ 402.12599 -3.2 402.1265, 382.1206, 364.1092, 352.1102, 343.0894, 329.0737, 316.0658 
TPSAR-6 402.1249 7.50 [C20H18N3O4F2]
+ 402.12599 -2.7 402.1264, 384.1160, 343.0887, 317.0735, 299.0624, 271.0675 
TPSAR-7 414.1616 5.95 [C22H22N3O3F2]
+ 414.16237 -1.9 414.1631, 386.1315, 366.1255, 343.0895, 325.0786, 299.0994 
TPSAR-8 416.1042 6.59 [C20H16N3O5F2]
+ 416.10525 -2.5 416.1057, 388.1107, 372.1165, 342.0683, 329.0745, 316.0662, 299.0651 
TPSAR-9 416.1053 6.84 [C20H16N3O5F2]
+ 416.10525 0.1 416.1058, 388.1111, 370.1005, 345.0686, 327.0576, 318.0578, 299.0632 
TPSAR-10 428.1414 8.03 [C22H20N3O4F2]
+ 428.14164 -0.6 428.1415, 410.1316, 386.1309, 366.1376, 343.0888, 329.0730, 325.0781 
TPSAR-11 488.1210 0.51 [C21H19N5O8F]
+ 488.12122 -0.5 488.1219, 470.1106, 462.1424, 444.1313 
TPSAR-12 516.1158 0.51 [C22H19N5O9F]
+ 516.11613 -0.6 516.1165, 502.0996, 474.1052, 448.1265, 430.1160, 420.1310, 404.1363, 402.1210, 386.1261 
(*) TPs from ENR also identified as metabolites in the chicken muscle samples (M1, M2, M3, M6, M8, M9, M11, M12, M13 and M14, 
respectively) 
 
 
 
 
Table 2. Mass spectral data, proposed structures and MS/MS spectrum for the identified 
metabolites of ENR in the medicated chicken samples. 
 
Compound [M+H]+exp 
RT 
(min) 
Molecular 
Formula 
[M+H]+theo 
m/z 
error 
(ppm) 
Proposed 
structure 
MS/MS spectrum 
ENR 360.1713 4.87 [C19H23N3O3F]
+ 360.1718 -1.4 
 
360.1721, 342.1613, 
340.1656, 316.1818, 
286.0985, 257.1084, 
245.1084, 231.0927 
M1 263.0822 6.77 [C13H12N2O3F]
+ 263.08265 -1.7 
 
Figure 5A 
M2 332.1405 4.59 [C17H19N3O3F]
+ 332.14050 0.0 
 
Figure 5B 
M3 334.1556 4.41 [C17H21N3O3F]
+ 334.15615 -1.6 
 
Figure 5C 
M4 342.1806 4.29 [C19H24N3O3]
+ 342.18122 -1.8 
 
Figure 5D 
M5 346.1552 4.65 [C18H21N3O3F]
+ 346.15615 -2.7 
 
346.1563, 328.1462, 
302.1665, 285.1278, 
257.1086, 245.1087, 
231.0929, 204.0693 
M6 348.1716 4.77 [C18H23N3O3F]
+ 348.17180 -0.6 
 
348.1718, 304.1818, 
273.1269, 245.1084, 
233.1084, 219.0927 
M7 372.1915 4.75 [C20H26N3O4]
+ 372.19178 -0.8 
 
372.1919, 328.2017, 
297.1470, 272.1400, 
257.1284, 241.0971, 
227.0813, 215.0811 
M8 374.1500 3.70 [C19H21N3O4F]
+ 374.15106 -2.8 
 
374.1510, 356.1411, 
346.1557, 314.0937, 
289.0981, 286.0985, 
275.0827, 271.0877, 
257.0724, 245.1093 
M9 374.1496 7.47 [C19H21N3O4F]
+ 374.15106 -3.9 
 
374.1511, 356.1406, 
332.1029, 314.1301, 
295.0951, 272.0829, 
243.0562, 231.0564 
M10 374.1701 4.69 [C19H24N3O5]
+ 374.17105 -2.5 
 
Figure 5E 
M11 376.1673 4.58 [C19H23N3O4F]
+ 376.16671 1.6 
 
376.1668, 358.1561, 
346.1548, 289.0983, 
275.0824, 262.0749, 
244.1012 
M12 376.1664 5.23 [C19H23N3O4F]
+ 376.16671 -0.8 
 
376.1669, 359.1639, 
344.1404, 330.1614, 
315.1740, 300.1507, 
287.1429 
M13 376.1657 5.84 [C19H23N3O4F]
+ 376.16671 -2.7 
 
376.1666, 332.1767, 
301.1219, 261.1036, 
247.0879, 220.0642 
M14 388.1302 6.63 [C19H19N3O5F]
+ 388.13033 -0.3 
 
388.1305, 360.1367, 
348.0995, 342.1262, 
330.0885, 320.1048, 
302.0571 
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